Q: Olink has been rapidly growing its’ library of human protein biomarker assays. What are the popular clinical applications for your biomarker panels?

A: At the beginning of 2017, Olink launched 5 new panels (over 450 new targets) and expanded its offering to include around 1,000 validated protein assays. Another milestone reached this year is that there are now over 100 publications that cite using Olink panels, quite impressive considering the very first panel only came out in 2014. Olink’s ability to cast a broad proteomics net and isolate biomarker profiles for tailored approaches is being used for patient stratification, better understanding of pathophysiology of disease, predictive disease biomarkers, surrogates and optimizing wellness. We also see these types of applications applied across a range of clinical areas, including cardiovascular, neurological, inflammatory and metabolic diseases and oncology. You can see the latest list of these publications at www.olink.com/publications

Q: What are the benefits of Olink’s immune-oncology biomarker panel for researchers and clinicians working on immunotherapy-based cancer treatments?

A: It is the most comprehensive immune-oncology related protein panel out there, looking at 92 proteins simultaneously in only 1 uL of basically any sample type. Personalized oncology treatments are changing the way that we approach cancer therapy. The success of these therapeutic approaches will depend on an understanding of the underlying genetic mutations and the confirmatory proteomic profile of the cancer. Accessing non-invasive biomarkers, such as proteins present in blood or tissue, for the immuno-oncology area offer great potential benefits in helping to better understand the underlying pathophysiology, study therapeutic efficacy and stratify patients for clinical trials. Immune responses are complex and dynamic in nature, so monitoring changes at the protein level is likely to be important here. The immuno-oncology panel casts a relatively broad net, while enabling a targeted approach to include proteins involved in processes such as promotion and inhibition of tumor immunity, chemotaxis, vascular & tissue remodeling, apoptosis & cell killing and metabolism & autophagy.

Q: What are the benefits of the Olink Proximity Extension Assay technology?

A: PEA, or Proximity Extension Assay, is elegantly simple in its approach. PEA consists of pairs of antibodies linked to DNA oligos that, upon antibody binding on the protein, are brought into proximity, hybridize and can then be extended by a DNA polymerase, creating a new sequence that can be used as a template for measurement by qPCR.
Two antibodies must bind to the target protein for a signal to be generated, i.e dual recognition, which together with the fidelity of the unique PCR template generated, reduces non-specific binding and background. This results in increased sensitivity and specificity in a very broad dynamic range, compared to conventional immunoassays. PEA is truly scalable, whether you are measuring 92 protein targets from one of our panels, or narrowing the signature to a subset of protein assays. We currently have configured our assays to require only 1 microliter of sample per panel. The researcher can run nearly 1,000 protein assays with less than 20 uL of sample, that is quite a powerful tool, which will further enable scientific discovery.

Q: What do you see as the future of protein profiling for clinical utility?

A: Multiplexed proteomics has historically lagged behind genomics in the clinical biomarker arena, but this can be attributed mainly to the technologies available. It is probably fair to say that most people working with biomarkers and precision medicine see the essential role for protein biomarkers going forwards and many have been waiting for the right tools to do this. PEA can change that, truly enabling a proteomics technology that is already making a big impact in discovery applications in clinical research. Custom protein signatures are now being brought into the clinic for more tailored treatment strategies. We experience that signatures based on several proteins will be more powerful and robust than single proteins. Having a technology like PEA that is truly scalable may have some real benefits in potentially translating the findings from broad screening discovery to clinical utility of validated signatures enabling precision medicine.

Call to the Health Care Community to Execute on Next Steps for a Wider Adoption and Implementation of Precision Medicine

The recent Facebook data breach, genetic data sleuthing by the FBI that led to the Golden State Killer, and the soon-to-be-implemented European General Data Protection Regulation (GDPR), has put data privacy and security front and center.

Read More

Data Privacy, the Security, And Ownership

The recent Facebook data breach, genetic data sleuthing by the FBI that led to the Golden State Killer, and the soon-to-be-implemented European General Data Protection Regulation (GDPR), has put data privacy and security front and center.

Read More

Q&A with Jason Crites from IBM & Piers Nash from Health2047 Speaking at PMWC 2018 Michigan in June

Q: What need is IBM and Health2047 addressing in the healthcare/life sciences sector?

Jason (IBM): The industry is undergoing a significant transformation as reimbursement shifts from fee-for-service to value-based outcomes in the face of regulatory uncertainty.

Read More

Dr. Francis Collins of NIH at June PMWC Michigan- Launch of Nationwide Participation Enrollment!

This past Sunday—May 6, 2018—the program reached a major milestone with the start of the nationwide participation enrollment! The All of Us Research Program, part of the Precision Medicine Initiative that was famously announced by President Barack Obama at the 2015 State of the Union address, aims to enroll a total of 1 million Americans.

Read More

Meet Dr. Gil Omenn, Director of the University of Michigan Center for Computational Medicine & Bioinformatics on June 6th at PMWC 2018 Michigan

Q: What are the objectives of the Human Proteome Project and what are some of the recent breakthrough discoveries?

The HUPO Human Proteome Project has two overarching goals: (1) to complete the protein parts list, with at least one protein product from each of the ~20,000 protein-coding genes along with sequence variants, splice variants, and post-translational modifications, with characterization of their functions;…

Read More

Meet Amir Dan Rubin, CEO of One Medical on June 6th at PMWC 2018 Michigan

Q: What are some of the biggest contributors to these challenges and how can we overcome them?

A: One of the underlying challenges driving the rising the cost of health care is that most of the health system’s stakeholders have few incentives, if not outright disincentives, to manage expenditures.

Read More

Interview with Steve Nelson, CEO, UnitedHealthcare Presenting at PMWC 2018 Michigan in June

Q: What’s the biggest misconception about UnitedHealthcare?

That we don’t care, that we’re just a health insurance company that pays or denies medical claims. In reality, helping people is at the core of what we do every day.

Read More

Emerging Technologies are Disrupting Healthcare | PMWC Michigan June 6-7

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine, Q&A with Eric Topol

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!